Skip to main
AVDL

Avadel Pharma (AVDL) Stock Forecast & Price Target

Avadel Pharma (AVDL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 13%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Avadel Pharmaceuticals PLC demonstrates a positive financial outlook driven by the anticipated growth of its product LUMRYZ, which may surpass $500 million in peak sales due to its convenient once-nightly dosing compared to existing treatments. The company has achieved cash flow positivity attributable to robust LUMRYZ sales since its approval in 2023, alongside strong patient adoption, with over 3,100 patients reported using the drug as of June 30. Furthermore, ongoing developments, including the pivotal trial for the idiopathic hypersomnia indication, are expected to yield favorable data, potentially expanding Avadel's market presence and offering additional growth opportunities.

Bears say

Avadel Pharmaceuticals faces significant challenges that contribute to a negative outlook on its stock. Key risks include the potential for slower-than-expected market uptake of LUMRYZ due to anticipated generic competition, pricing pressures, and the uncertainty surrounding ongoing patent litigation, which may hinder effective commercialization efforts. Additionally, the failure of the Phase 3 trial for idiopathic hypersomnia and setbacks associated with other drug candidates pose considerable clinical and financial hurdles for the company.

Avadel Pharma (AVDL) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avadel Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avadel Pharma (AVDL) Forecast

Analysts have given Avadel Pharma (AVDL) a Buy based on their latest research and market trends.

According to 8 analysts, Avadel Pharma (AVDL) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avadel Pharma (AVDL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.